CN109476649A - 五元杂环类化合物及其制备方法、药物组合物和用途 - Google Patents

五元杂环类化合物及其制备方法、药物组合物和用途 Download PDF

Info

Publication number
CN109476649A
CN109476649A CN201780024801.3A CN201780024801A CN109476649A CN 109476649 A CN109476649 A CN 109476649A CN 201780024801 A CN201780024801 A CN 201780024801A CN 109476649 A CN109476649 A CN 109476649A
Authority
CN
China
Prior art keywords
compound
group
alkyl
formula
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780024801.3A
Other languages
English (en)
Other versions
CN109476649B (zh
Inventor
罗成
姚志艺
乔刚
蒋华良
周宇
陈丽敏
刘静秋
丁宏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Suplead Life Sciences Co ltd
Shanghai Institute of Materia Medica of CAS
Original Assignee
Suzhou Suplead Life Sciences Co ltd
Shanghai Institute of Materia Medica of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Suplead Life Sciences Co ltd, Shanghai Institute of Materia Medica of CAS filed Critical Suzhou Suplead Life Sciences Co ltd
Priority claimed from PCT/CN2017/081293 external-priority patent/WO2017181973A1/zh
Publication of CN109476649A publication Critical patent/CN109476649A/zh
Application granted granted Critical
Publication of CN109476649B publication Critical patent/CN109476649B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

本发明提供了一类五元杂环类化合物及其制备方法、药物组合物和用途，具体地，本发明提供了一类具有如下式(I)化合物，其中，各基团的定义如说明书中所述。所述的式I化合物具有抑制微管蛋白活性的效果，可以用于制备治疗或预防与微管蛋白调节异常相关的哺乳动物疾病的药物。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN201780024801.3A 2016-04-20 2017-04-20 五元杂环类化合物及其制备方法、药物组合物和用途 Active CN109476649B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2016102476581 2016-04-20
CN201610247658 2016-04-20
CN201610880966.8A CN107304203A (zh) 2016-04-20 2016-10-09 五元杂环类化合物及其制备方法、药物组合物和用途
CN2016108809668 2016-10-09
PCT/CN2017/081293 WO2017181973A1 (zh) 2016-04-20 2017-04-20 五元杂环类化合物及其制备方法、药物组合物和用途

Publications (2)

Publication Number Publication Date
CN109476649A true CN109476649A (zh) 2019-03-15
CN109476649B CN109476649B (zh) 2022-07-08

Family

ID=60150661

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201610880829.4A Pending CN107304202A (zh) 2016-04-20 2016-10-09 五元杂环类化合物及其制备方法、药物组合物和用途
CN201610880966.8A Pending CN107304203A (zh) 2016-04-20 2016-10-09 五元杂环类化合物及其制备方法、药物组合物和用途
CN201780024845.6A Active CN109476650B (zh) 2016-04-20 2017-04-20 五元杂环类化合物及其制备方法、药物组合物和用途
CN201780024801.3A Active CN109476649B (zh) 2016-04-20 2017-04-20 五元杂环类化合物及其制备方法、药物组合物和用途

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CN201610880829.4A Pending CN107304202A (zh) 2016-04-20 2016-10-09 五元杂环类化合物及其制备方法、药物组合物和用途
CN201610880966.8A Pending CN107304203A (zh) 2016-04-20 2016-10-09 五元杂环类化合物及其制备方法、药物组合物和用途
CN201780024845.6A Active CN109476650B (zh) 2016-04-20 2017-04-20 五元杂环类化合物及其制备方法、药物组合物和用途

Country Status (1)

Country Link
CN (4) CN107304202A (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114507244A (zh) * 2020-11-16 2022-05-17 广州市恒诺康医药科技有限公司 咪唑并噻唑类化合物、其药物组合物及其用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112142744A (zh) * 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064674A1 (en) * 2000-03-01 2001-09-07 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
CN1426413A (zh) * 2000-04-27 2003-06-25 山之内制药株式会社 咪唑并吡啶衍生物
WO2010002987A1 (en) * 2008-07-01 2010-01-07 Ptc Therapeutics, Inc Methods for screening for compounds for treating cancer
WO2010002985A1 (en) * 2008-07-01 2010-01-07 Ptc Therapeutics, Inc. Bmi-1 protein expression modulators
WO2010017047A1 (en) * 2008-08-05 2010-02-11 Merck & Co., Inc. Therapeutic compounds
WO2012068204A1 (en) * 2010-11-18 2012-05-24 Janssen Pharmaceutica Nv Fused heteroaryl inhibitors of pro-matrix metalloproteinase activation
CN102822173A (zh) * 2010-02-19 2012-12-12 美国艾森生物科学公司 杂环化合物和作为抗癌剂的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ546057A (en) * 2003-12-03 2010-04-30 Ym Bioscience Australia Pty Lt Tubulin inhibitors
CN101193884A (zh) * 2005-06-13 2008-06-04 惠氏公司 微管蛋白抑制剂和其制备方法
US9187521B2 (en) * 2007-10-25 2015-11-17 Endocyte, Inc. Tubulysins and processes for preparing
CA2757573A1 (en) * 2009-04-16 2010-10-21 Telik, Inc. Substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carbonitriles and substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carboxamides as tubulin polymerization inhibitors
EP2322537A1 (en) * 2009-11-12 2011-05-18 R & D Biopharmaceuticals Gmbh Tubulin inhibitors
CN103193691B (zh) * 2012-01-06 2017-08-25 中国科学院上海药物研究所 磺胺类化合物、药物组合物及其制法和应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064674A1 (en) * 2000-03-01 2001-09-07 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
CN1426413A (zh) * 2000-04-27 2003-06-25 山之内制药株式会社 咪唑并吡啶衍生物
WO2010002987A1 (en) * 2008-07-01 2010-01-07 Ptc Therapeutics, Inc Methods for screening for compounds for treating cancer
WO2010002985A1 (en) * 2008-07-01 2010-01-07 Ptc Therapeutics, Inc. Bmi-1 protein expression modulators
WO2010017047A1 (en) * 2008-08-05 2010-02-11 Merck & Co., Inc. Therapeutic compounds
CN102822173A (zh) * 2010-02-19 2012-12-12 美国艾森生物科学公司 杂环化合物和作为抗癌剂的用途
WO2012068204A1 (en) * 2010-11-18 2012-05-24 Janssen Pharmaceutica Nv Fused heteroaryl inhibitors of pro-matrix metalloproteinase activation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114507244A (zh) * 2020-11-16 2022-05-17 广州市恒诺康医药科技有限公司 咪唑并噻唑类化合物、其药物组合物及其用途
CN114507244B (zh) * 2020-11-16 2023-10-27 广州市恒诺康医药科技有限公司 咪唑并噻唑类化合物、其药物组合物及其用途

Also Published As

Publication number Publication date
CN109476649B (zh) 2022-07-08
CN107304203A (zh) 2017-10-31
CN109476650B (zh) 2022-11-25
CN107304202A (zh) 2017-10-31
CN109476650A (zh) 2019-03-15

Similar Documents

Publication Publication Date Title
CN109422752A (zh) 一类具有抑制并降解布鲁顿酪氨酸蛋白激酶Btk活性的化合物
EP3184521A1 (en) Indazole compounds as fgfr kinase inhibitor, preparation and use thereof
KR20180042368A (ko) 축합 피리미딘 화합물 또는 그의 염
EP3048108B1 (en) Thienopiperidine derivative and use thereof
CN106279147A (zh) 一种吡啶并氮杂环化合物及其制备方法和用途
CN109422733A (zh) 一类抑制并降解酪氨酸蛋白激酶alk的化合物
JP2011527291A (ja) 塩酸イコチニブ、合成物、結晶学的形態、併用薬及びその用途
EP2868660B1 (en) Antitumor effect potentiator comprising an imidazooxazine compound
Zou et al. Synthesis and evaluation of N-heteroaromatic ring-based analogs of piperlongumine as potent anticancer agents
CN104557940A (zh) Bcr-abl激酶抑制剂及其应用
EP4029862A1 (en) Compound having axl and c-met kinase inhibitory activity, preparation thereof and application thereof
CN105732616A (zh) 含联芳基酰胺结构的吡咯并吡啶类化合物及其制备方法和应用
EP3418277B1 (en) Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof
US20150306070A1 (en) Use of maleimide derivatives for preventing and treating leukemia
WO2017181974A1 (zh) 五元杂环类化合物及其制备方法、药物组合物和用途
CN109476649A (zh) 五元杂环类化合物及其制备方法、药物组合物和用途
CN109111426A (zh) 一类稠合双环杂芳基或芳基化合物，及其用途
US10301325B2 (en) Quinoline derivative, and pharmaceutical composition, preparation method and use thereof
EP3036227B1 (en) Process for preparing a compound
CN113214230B (zh) 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
WO2017181973A1 (zh) 五元杂环类化合物及其制备方法、药物组合物和用途
CN101423513B (zh) 胺基嘧啶衍生物、及其制法和药物组合物与用途
EP3098222B1 (en) Fused acridine derivative and pharmaceutical composition, preparation method and use thereof
CN108570039A (zh) 一类具有抑制抗凋亡蛋白活性的化合物及其制备和应用
CN102219745B (zh) 2-芳基取代苯并咪唑类衍生物及其制备方法与应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant